Lipoprotein metabolism: A well-tried tool to characterize dyslipidemic mechanisms

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 6, 2006, Pages 1201-1203

  Berglund, Lars ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; VERY LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIRCULATION TIME; COMPARATIVE STUDY; DYSLIPIDEMIA; EDITORIAL; ENZYME DEFICIENCY; HUMAN; LIPID METABOLISM; LIPOPROTEIN METABOLISM; METABOLIC REGULATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; HYPOLIPOPROTEINEMIA; METABOLISM; NOTE;

DYSLIPIDEMIAS; HUMANS; LECITHIN ACYLTRANSFERASE DEFICIENCY; LIPOPROTEINS; LIPOPROTEINS, LDL;

EID: 33745043101     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000217281.06795.61     Document Type: Editorial

References (17)

1. Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M, Johansson J, Salvetti M, Monteduro C, Zulli R, Muiesan ML, Agabiti-Rosei E. Cardiovascular status of the carriers of apolipoprotein A-I (Milano) mutant: the Limone sul Gardia study. Circulation. 2001;103:1949-1954.
2. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. J Am Med Assoc. 2003;290:2292-2300.
3. Glomset JA, Norum KR, King W. Plasma lipoproteins in familial lecithin: cholesterol acyltransferase deficiency: lipid composition and reactivity in vitro. J Clin Invest. 1970;49:1827-1837.
4. Norum KR, Gjone E. Familial lecithin:cholesterol acyltransferase deficiency. Biochemical study of a new inborn error of metabolism. Scand J Clin Lab Invest. 1967;20:231-243.
5. Glomset JA, Assman G, Gjone E, Norum KR. Lecithin:cholesterol acyltransferase deficiency and fish eye disease. In: Scriver CR, Beaudet AL, Sly WS, Standbury JB, Wyngaarden JB, Fredrickson DS, eds. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill 1995, 1933-1951.
6. Assman G, von Eckardstein A, Funke H. Lecithin:cholesterol acyltransferase deficiency and fish eye disease. Curr Opin Lipidol. 1991;2:110-117.
7. Jonas A. Lecithin: cholesterol acyltransferase. Biochim Biophys Acta. 2000;1529:245-256.
8. Glomset JA, Nichols AV, Norum KR, King W, Forte T. Plasma lipoproteins in familial lecithin:cholesterol acyltransferase deficiency: further studies of very low and low density lipoprotein abnormalities. J Clin Invest. 1978;52:1078-1092.
9. Deeb SS, Zambon A, Carr MC, Ayyobi AF, Brunzell JD. Hepatic lipase and dyslipidemia: interactions between genetic variants, obesity, gender and diet. J Lipid Res. 2003;44:1279-1286.
10. Nishiwaki M, Ikewaki K, Bader G, Nazih H, Shamburek RD, Hannuksela M, Remaley AT, Brewer HB Jr. Human lecithin:cholesterol acyltransferase deficiency: in vivo kinetics of low density lipoprotein and lipoprotein-X. Arterioscler Thromb Vasc Biol. 2006;26:1370-1375.
11. Young SG, Witztum JL, Carew TE, Krauss RM, Lindgren FT. Colestipol-induced changes in LDL composition and metabolism. II: Studies in humans. J Lipid Res. 1989;30:225-238.
12. Berglund L, Sharkey MF, Elam RL, Witztum JL. Effect of lovastatin therapy on guinea pig low density lipoprotein composition and metabolism. J Lipid Res. 1989;30:1591-1600.
13. Berglund L, Witztum JL, Galeano NF, Khouw AS, Ginsberg HN, Ramakrishnan R. Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach. J Lipid Res. 1998;39:913-924.
14. Ayyobi AF, McGladdery SH, Chan S, Mancini GBJ, Hill JS, Frohlich JJ. Lecithin: cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis. 2004;177:361-366.
15. Berard AM, Clerc M, Brewer HB Jr, Santamarina-Fojo S. A normal rate of cellular cholesterol removal can be mediated by plasma from a patient with lecithin:cholesterol acyltransferase (LCAT) deficiency. Clin Chim Acta. 2001;314:131-139.
16. Calabresi L, Pisciotta L, Constantin A, Frigerio I, Eberini I, Alessandrini P, Arca M, Bittolo Bon G, Boscutti G, Busnach G, Frasca G, Gesualdo L, Gigante M, Lupattelli G, Montali A, Pizzolitto S, Rabbone I, Rolleri M, Ruotolo G, Sampietro T, Sessa A, Vaudo G, Cantafora A, Veglia F, Calandra S, Bertolini S, Franceschini G. The molecular basis of lecithin: cholesterol acyltransferase deficiency syndromes. A comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol. 2005;25:1972-1978.
17. Miettinen HE, Gylling H, Tanhunen J, Virtamo J, Jauhiainen M, Huttunen JK, Kantola I, Miettinen JA, Kontula K. Molecular genetic study of Finns with hypoalphalipoproteinemia and hyperalphalipoproteinemia: a novel Gly230Arg mutation (LCAT[Fin]) of lecithin:cholesterol acyltransferase (LCAT) accounts for 5% of cases with very low serum HDL cholesterol levels. Arterioscler Thromb Vasc Biol. 1998;18:591-598.